vs
爱彼迎（ABNB）与波士顿科学（BSX）财务数据对比。点击上方公司名可切换其他公司
波士顿科学的季度营收约是爱彼迎的1.9倍（$5.2B vs $2.8B），波士顿科学净利率更高（25.7% vs 12.3%，领先13.5%），爱彼迎同比增速更快（12.0% vs 11.6%），过去两年爱彼迎的营收复合增速更高（13.9% vs 12.4%）
爱彼迎是全球知名的旅行住宿及体验共享平台，成立于2007年，2010年正式启用现名。平台连接全球各地的房东与旅客，用户可通过网页或移动端预订私人客房、普通住宅、度假屋等多元住宿，也可报名参与当地特色体验项目，是共享经济领域的代表性企业。
波士顿科学是一家美国跨国生物科技与生物医学工程企业，专注于介入医学领域医疗设备的研发生产，产品覆盖介入心内科、介入放射科、神经调控、肿瘤、泌尿、妇科、内镜、心脏及血管外科等多个专科诊疗场景。
ABNB vs BSX — 直观对比
营收规模更大
BSX
是对方的1.9倍
$2.8B
营收增速更快
ABNB
高出0.4%
11.6%
净利率更高
BSX
高出13.5%
12.3%
两年增速更快
ABNB
近两年复合增速
12.4%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.8B | $5.2B |
| 净利润 | $341.0M | $1.3B |
| 毛利率 | 82.5% | 69.5% |
| 营业利润率 | 9.7% | — |
| 净利率 | 12.3% | 25.7% |
| 营收同比 | 12.0% | 11.6% |
| 净利润同比 | -26.0% | 99.0% |
| 每股收益（稀释后） | — | $0.90 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABNBBSX
| Q1 26 | — | $5.2B | ||
| Q4 25 | $2.8B | $5.3B | ||
| Q3 25 | $4.1B | $5.1B | ||
| Q2 25 | $3.1B | $5.1B | ||
| Q1 25 | $2.3B | $4.7B | ||
| Q4 24 | $2.5B | $4.6B | ||
| Q3 24 | $3.7B | $4.2B | ||
| Q2 24 | $2.7B | $4.1B |
净利润ABNBBSX
| Q1 26 | — | $1.3B | ||
| Q4 25 | $341.0M | $670.0M | ||
| Q3 25 | $1.4B | $755.0M | ||
| Q2 25 | $642.0M | $795.0M | ||
| Q1 25 | $154.0M | $672.0M | ||
| Q4 24 | $461.0M | $563.0M | ||
| Q3 24 | $1.4B | $468.0M | ||
| Q2 24 | $555.0M | $322.0M |
毛利率ABNBBSX
| Q1 26 | — | 69.5% | ||
| Q4 25 | 82.5% | 69.6% | ||
| Q3 25 | 86.6% | 69.9% | ||
| Q2 25 | 82.4% | 67.7% | ||
| Q1 25 | 77.7% | 68.8% | ||
| Q4 24 | 82.8% | 67.8% | ||
| Q3 24 | 87.5% | 68.8% | ||
| Q2 24 | 81.6% | 69.2% |
营业利润率ABNBBSX
| Q1 26 | — | — | ||
| Q4 25 | 9.7% | 15.6% | ||
| Q3 25 | 39.7% | 20.7% | ||
| Q2 25 | 19.8% | 16.2% | ||
| Q1 25 | 1.7% | 19.8% | ||
| Q4 24 | 17.3% | 14.8% | ||
| Q3 24 | 40.9% | 17.4% | ||
| Q2 24 | 18.1% | 12.6% |
净利率ABNBBSX
| Q1 26 | — | 25.7% | ||
| Q4 25 | 12.3% | 12.7% | ||
| Q3 25 | 33.6% | 14.9% | ||
| Q2 25 | 20.7% | 15.7% | ||
| Q1 25 | 6.8% | 14.4% | ||
| Q4 24 | 18.6% | 12.3% | ||
| Q3 24 | 36.7% | 11.1% | ||
| Q2 24 | 20.2% | 7.8% |
每股收益（稀释后）ABNBBSX
| Q1 26 | — | $0.90 | ||
| Q4 25 | — | $0.45 | ||
| Q3 25 | — | $0.51 | ||
| Q2 25 | — | $0.53 | ||
| Q1 25 | — | $0.45 | ||
| Q4 24 | — | $0.38 | ||
| Q3 24 | — | $0.32 | ||
| Q2 24 | — | $0.22 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $11.0B | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $8.2B | — |
| 总资产 | $22.2B | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABNBBSX
| Q1 26 | — | — | ||
| Q4 25 | $11.0B | $2.0B | ||
| Q3 25 | $11.7B | $1.3B | ||
| Q2 25 | $11.4B | $534.0M | ||
| Q1 25 | $11.5B | $725.0M | ||
| Q4 24 | $10.6B | $414.0M | ||
| Q3 24 | $11.3B | $2.5B | ||
| Q2 24 | $11.3B | $2.9B |
总债务ABNBBSX
| Q1 26 | — | — | ||
| Q4 25 | — | $11.1B | ||
| Q3 25 | — | $11.1B | ||
| Q2 25 | — | $11.1B | ||
| Q1 25 | — | $10.5B | ||
| Q4 24 | — | $9.0B | ||
| Q3 24 | — | $9.2B | ||
| Q2 24 | — | $9.0B |
股东权益ABNBBSX
| Q1 26 | — | — | ||
| Q4 25 | $8.2B | $24.2B | ||
| Q3 25 | $8.6B | $23.4B | ||
| Q2 25 | $7.8B | $22.4B | ||
| Q1 25 | $7.9B | $22.2B | ||
| Q4 24 | $8.4B | $21.8B | ||
| Q3 24 | $8.5B | $20.7B | ||
| Q2 24 | $8.0B | $20.4B |
总资产ABNBBSX
| Q1 26 | — | — | ||
| Q4 25 | $22.2B | $43.7B | ||
| Q3 25 | $23.1B | $42.7B | ||
| Q2 25 | $27.0B | $41.6B | ||
| Q1 25 | $25.1B | $40.1B | ||
| Q4 24 | $21.0B | $39.4B | ||
| Q3 24 | $22.2B | $38.1B | ||
| Q2 24 | $26.3B | $37.1B |
负债/权益比ABNBBSX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.46× | ||
| Q3 25 | — | 0.48× | ||
| Q2 25 | — | 0.50× | ||
| Q1 25 | — | 0.47× | ||
| Q4 24 | — | 0.41× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.44× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $526.0M | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 1.54× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ABNBBSX
| Q1 26 | — | — | ||
| Q4 25 | $526.0M | $1.4B | ||
| Q3 25 | $1.4B | $1.3B | ||
| Q2 25 | $975.0M | $1.3B | ||
| Q1 25 | $1.8B | $541.0M | ||
| Q4 24 | $466.0M | $1.5B | ||
| Q3 24 | $1.1B | $1.0B | ||
| Q2 24 | $1.1B | $813.0M |
自由现金流ABNBBSX
| Q1 26 | — | — | ||
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $354.0M | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $823.0M | ||
| Q2 24 | — | $658.0M |
自由现金流率ABNBBSX
| Q1 26 | — | — | ||
| Q4 25 | — | 19.2% | ||
| Q3 25 | — | 22.9% | ||
| Q2 25 | — | 22.3% | ||
| Q1 25 | — | 7.6% | ||
| Q4 24 | — | 25.8% | ||
| Q3 24 | — | 19.6% | ||
| Q2 24 | — | 16.0% |
资本支出强度ABNBBSX
| Q1 26 | — | — | ||
| Q4 25 | — | 6.6% | ||
| Q3 25 | — | 3.6% | ||
| Q2 25 | — | 3.1% | ||
| Q1 25 | — | 4.0% | ||
| Q4 24 | — | 6.1% | ||
| Q3 24 | — | 4.3% | ||
| Q2 24 | — | 3.8% |
现金转化率ABNBBSX
| Q1 26 | — | — | ||
| Q4 25 | 1.54× | 2.04× | ||
| Q3 25 | 0.99× | 1.78× | ||
| Q2 25 | 1.52× | 1.62× | ||
| Q1 25 | 11.62× | 0.81× | ||
| Q4 24 | 1.01× | 2.59× | ||
| Q3 24 | 0.79× | 2.14× | ||
| Q2 24 | 1.89× | 2.52× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABNB
| North America | $1.1B | 41% |
| EMEA | $930.0M | 33% |
| Latin America | $351.0M | 13% |
| Other | $351.0M | 13% |
BSX
| Cardiovascular | $3.1B | 59% |
| Endoscopy | $673.0M | 13% |
| Urology | $633.0M | 12% |
| Other | $386.0M | 7% |
| Neuromodulation | $271.0M | 5% |
| LACA | $155.0M | 3% |
